Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Mycophenolic acid 180mg gastro-resistant tablets
0802010N0AAAAAA
|
Mycophenolic sodium | Mycophenolic sodium | Malignant Disease and Immunosuppression | 466 |
|
Megace 160mg tablets
0803020L0BBACAB
|
Megace | Megestrol acetate | Malignant Disease and Immunosuppression | 460 |
|
Sirolimus 2mg tablets
0802020U0AAAEAE
|
Sirolimus | Sirolimus | Malignant Disease and Immunosuppression | 443 |
|
Fluorouracil 4% cream
0801030H0AABLBL
|
Fluorouracil (Antimetabolites) | Fluorouracil (Antimetabolites) | Malignant Disease and Immunosuppression | 419 |
|
Gonapeptyl Depot 3.75mg inj pre-filled syringes
0803042P0BCAAAB
|
Gonapeptyl Depot | Triptorelin acetate | Malignant Disease and Immunosuppression | 417 |
|
Methotrexate 25mg/1ml inj pre-filled disposable devices
0801030P0AAFUFU
|
Methotrexate | Methotrexate | Malignant Disease and Immunosuppression | 404 |
|
Adoport 0.75mg capsules
0802020T0BEADBF
|
Adoport | Tacrolimus | Malignant Disease and Immunosuppression | 395 |
|
Tacrolimus 1mg capsules
0802020T0AAABAB
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 379 |
|
Triptorelin acetate 3mg inj vials
0803042P0AAAAAA
|
Triptorelin (acetate) | Triptorelin acetate | Malignant Disease and Immunosuppression | 374 |
|
Lanreotide 120mg/0.5ml inj pre-filled syringes
0803043P0AAADAD
|
Lanreotide | Lanreotide | Malignant Disease and Immunosuppression | 371 |
|
Firmagon 80mg inj vials
0803042R0BBAAAA
|
Firmagon | Degarelix | Malignant Disease and Immunosuppression | 369 |
|
Nordimet 22.5mg/0.9ml solution for injection pre-filled pens
0801030P0BFAGFT
|
Nordimet | Methotrexate | Malignant Disease and Immunosuppression | 369 |
|
Ciclosporin 100mg capsules
0802020G0AAADAD
|
Ciclosporin (Systemic) | Ciclosporin | Malignant Disease and Immunosuppression | 330 |
|
Tolak 40mg/g cream
0801030H0BGAABL
|
Tolak | Fluorouracil (Antimetabolites) | Malignant Disease and Immunosuppression | 316 |
|
Methotrexate 15mg/0.6ml inj pre-filled disposable devices
0801030P0AAFQFQ
|
Methotrexate | Methotrexate | Malignant Disease and Immunosuppression | 313 |
|
Ciclosporin 25mg capsules
0802020G0AAACAC
|
Ciclosporin (Systemic) | Ciclosporin | Malignant Disease and Immunosuppression | 299 |
|
Nordimet 7.5mg/0.3ml solution for injection pre-filled pens
0801030P0BFAAFM
|
Nordimet | Methotrexate | Malignant Disease and Immunosuppression | 295 |
|
Sandostatin LAR 30mg inj vials
0803043N0BBAFAF
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | 277 |
|
Prograf 5mg capsules
0802020T0BBAAAA
|
Prograf | Tacrolimus | Malignant Disease and Immunosuppression | 271 |
|
Deximune 50mg capsules
0802020G0BEABAF
|
Deximune | Ciclosporin | Malignant Disease and Immunosuppression | 254 |
|
Myfortic 180mg gastro-resistant tablets
0802010N0BBAAAA
|
Myfortic | Mycophenolic sodium | Malignant Disease and Immunosuppression | 254 |
|
Octreotide 100micrograms/1ml solution for injection ampoules
0803043N0AAABAB
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 244 |
|
Mercaptopurine 10mg tablets
0801030L0AAABAB
|
Mercaptopurine | Mercaptopurine | Malignant Disease and Immunosuppression | 243 |
|
Azathioprine 50mg/5ml oral suspension
0802010G0AACHCH
|
Azathioprine | Azathioprine | Malignant Disease and Immunosuppression | 232 |
|
Octreotide 500micrograms/1ml solution for injection ampoules
0803043N0AAACAC
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 227 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.